Increasing Joint Strain Ahead of Chuseok... Prevention with "Max Chondroitin 1200"

As the weather quickly turns colder and the Chuseok holiday approaches-a time when seniors tend to be more active-there is growing interest in joint health management. In particular, the knees are especially vulnerable to degenerative arthritis due to the heavy load they bear from body weight.

According to the Health Insurance Review and Assessment Service as of 2022, there were approximately 4.18 million patients with degenerative arthritis, an increase of more than 300,000 compared to 2018. Notably, the number of patients surged after their 50s, and the proportion of female patients with low bone density was twice that of males. These figures indicate that the parent generation is in a high-risk group for joint diseases.

Against this backdrop, children are increasingly concerned about managing their parents’ health ahead of the holiday. If left untreated, joint pain can not only limit daily activities but also increase the risk of falls or fractures. In addition, degenerative arthritis can easily become chronic if early treatment opportunities are missed, making early intervention and consistent management essential.

Recently, chondroitin-based treatments available at local pharmacies have gained attention as an alternative to help alleviate symptoms of degenerative arthritis. Dong-A Pharmaceutical’s Max Chondroitin 1200 contains 1,200 mg of chondroitin sulfate sodium per dose, the highest single-dose amount available in Korea.

Chondroitin is a substance widely distributed in connective tissues such as cartilage, bones, and the cornea, and is a key component of the elastic fibers that protect cartilage. Taking chondroitin may help reduce symptoms of degenerative arthritis.

Max Chondroitin 1200 is the first oral gel-type chondroitin product in Korea, making it more convenient to consume compared to other forms. According to a clinical trial published in an SCIE journal, the gel-type chondroitin formulation reduced degenerative arthritis symptoms by 24% after 14 days and by 40% after 42 days of use.

In particular, when the chondroitin gel-type formulation was taken continuously for 90 days, symptoms of degenerative arthritis were alleviated by 50%, and the effect was sustained.

This content was produced with the assistance of AI translation services.